POLYPHOR
Polyphor is a Swiss Pharma company focusing on the discovery and development of macrocycle drugs addressing high unmet medical needs. Polyphor was founded in 1996 and is a clinical stage, privately held Swiss specialty pharma company, based in Allschwil near Basel. It focuses on the development of macrocycle drugs that address antibiotic resistance and severe respiratory diseases.
POLYPHOR
Industry:
Biotechnology Medical Pharmaceutical
Founded:
1996-01-01
Address:
Allschwil, Basel-Landschaft, Switzerland
Country:
Switzerland
Website Url:
http://www.polyphor.com
Total Employee:
51+
Status:
Active
Contact:
41615671601
Email Addresses:
[email protected]
Total Funding:
87.47 M USD
Technology used in webpage:
SPF LetsEncrypt Domain Not Resolving Euro Microsoft Exchange Online Office 365 Mail OpenResty Microsoft DNS
Similar Organizations
Aprea
Aprea focuses on the discovery and development of novel anticancer compounds reactivating the tumor suppressor protein p53.
PaxVax
PaxVax is a start-up developing candidate oral vaccines for key infectious diseases.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Salix Pharmaceuticals
Salix Pharmaceuticals is a specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders.
Versameb
Versameb is focusing on the discovery and development of innovative, next-generation RNA-based drugs.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2021-09-01 | EnBiotix | EnBiotix acquired by Polyphor | N/A |
Investors List
CARB-X
CARB-X investment in Grant - Polyphor
Cystic Fibrosis Foundation
Cystic Fibrosis Foundation investment in Grant - Polyphor
CARB-X
CARB-X investment in Grant - Polyphor
CARB-X
CARB-X investment in Grant - Polyphor
Repair Impact Fund
Repair Impact Fund investment in Post-IPO Equity - Polyphor
Novartis Venture Fund
Novartis Venture Fund investment in Venture Round - Polyphor
New Medical Technologies
New Medical Technologies investment in Venture Round - Polyphor
Official Site Inspections
http://www.polyphor.com
- Host name: s062.cyon.net
- IP address: 149.126.4.71
- Location: Switzerland
- Latitude: 47.1449
- Longitude: 8.1551
- Timezone: Europe/Zurich
More informations about "Polyphor" on Search Engine
About Spexis – Spexis
Spexis was created in December 2021 through the merger of EnBiotix, Inc., a privately held US biotech, into Polyphor AG, a publicly listed Swiss biotechnology company.See details»
Spexis - Crunchbase Company Profile & Funding
Polyphor is a Swiss Pharma company focusing on the discovery and development of macrocycle drugs addressing high unmet medical needs. Polyphor was founded in 1996 …See details»
Polyphor Closes Merger with EnBiotix and is Renamed Spexis
Dec 30, 2021 The portfolio and pipeline of the company going forward will be a combination of the two legacy companies, Polyphor and EnBiotix, and Polyphor has been renamed …See details»
Polyphor Closes Merger with EnBiotix and is Renamed Spexis
Dec 30, 2021 Pursuant to completion of the capital increase approved at the extraordinary general meeting of shareholders convened on October 28, 2021, Polyphor and EnBiotix, …See details»
POLYPHOR - Spexis
3 Polyphor provides multiple near-term pipeline progress and key value inflection points Balixafortide Potentially best-in-class CXCR4 inhibitor Phase III first co-primary endpoint …See details»
Macrocycle discovery platform – Spexis
Macrocycles, new modalities to address challenging biological targets. Polyphor’s peptidic and non-peptidic diverse macrocycles designed to mimic key naturally occurring epitopes …See details»
Spexis Company Profile - Office Locations, Competitors, …
2 days ago Spexis (formerly Polyphor) is a bioengineering company that specializes in respiratory therapeutics. It utilizes synthetic biology technologies to develop anti …See details»
Polyphor closes merger with EnBiotix and is renamed Spexis
Dec 30, 2021 Polyphor closes merger with EnBiotix and is renamed Spexis. December 30, 2021 at 01:21 am EST. 1263314 30-Dec-2021 CET/CEST. © EQS - 2021. Stock Market. …See details»
UPDATE: Roche Ends Antibiotic Collaboration with Polyphor
November 30, 2015. Roche has ended a two-year-old collaboration with Polyphor to develop and commercialize its macrocycle antibiotic candidate POL7080, designed to …See details»
Polyphor: Progress immuno-oncology program & renewed …
Polyphor AG (SIX: POLN), a research based clinical stage biopharmaceutical company, announces today progress of the Phase III immuno-oncology program with balixafortide …See details»
Roche and Polyphor join efforts to combat multi-drug-resistant ...
Nov 4, 2013 Roche (SIX: RO, ROG; OTCQX: RHHBY) and Polyphor Ltd., a privately held pharmaceutical company, announced today that they have entered into an exclusive …See details»
Polyphor and EnBiotix Announce Signing of Merger Agreement …
Sep 1, 2021 ALLSCHWIL, SWITZERLAND / ACCESSWIRE / September 1, 2021 / Polyphor (SIX:POLN) and EnBiotix Inc., a privately held late clinical-stage rare disease …See details»
Annual Report 2020 - Spexis
Polyphor at a glance We are a research-driven clinical-stage biopharmaceutical company based in Allschwil, Switzerland, committed to discovering and developing first-in-class …See details»
Polyphor receives up to 18 million dollars for development of ...
15.10.2020. The Allschwil-based company Polyphor has received a second funding award from the global consortium CARB-X to combat antimicrobial resistance. Polyphor will be …See details»
Polyphor AG - startup.ch
Novel antibiotics, oncology treatments and respiratory agent. Polyphor is a clinical stage, privately held Swiss specialty pharma company which has discovered and is developing …See details»
Polyphor Announces Financial Results for the Full-Year 2020
Mar 5, 2021 ALLSCHWIL, Switzerland, March 05, 2021 (GLOBE NEWSWIRE) -- Polyphor AG (SIX: POLN) a research driven clinical stage, Swiss biopharmaceutical company …See details»
POLYPHOR Corporate Strategy Update: Focus Forward
POLYPHOR. Corporate Strategy Update: Focus Forward. January, 2021. Forward-looking statement. This presentation (the “Presentation”) has been prepared by Polyphor Ltd. …See details»
POLYPHOR
Polyphor Highlights New strategy for antibiotics research and development applying the learning from our experience to enhance future clinical success. Restructured existing …See details»
Polyphor announces progress of the Phase III immuno-oncology …
Feb 20, 2020 Polyphor AG (SIX: POLN), a research based clinical stage biopharmaceutical company, announces today progress of the Phase III immuno …See details»
Polyphor announces changes to its Board of Directors
Nov 20, 2019 Bookmark. Wednesday, November 20, 2019 @ 10:00 am. Polyphor AG (SIX: POLN) announced today that Chairman of the Board Argeris "Jerry" Karabelas has …See details»